undamentalytics Newsletter
Sign in

Orthopediatrics Corp key statistics and ratios

In fiscal 2025, Orthopediatrics Corp had return on equity of -11.3% and a net margin of -16.8%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Net margin−25.5%−17.6%−19.6%−20.9%−18.9%−46.3%−16.6%1.0%−14.1%−18.5%−16.8%−12.8%
Return on equity———−18.6%−12.3%−17.5%−7.1%0.4%−5.6%−10.3%−11.3%−9.9%
Return on assets—−21.4%−15.8%−12.4%−9.3%−13.1%−5.2%0.3%−4.8%−8.3%−8.1%−6.7%
R&D as % of revenue5.8%6.0%7.5%8.2%7.9%7.4%5.7%6.9%7.3%5.4%3.9%3.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 7 checks passed · September 30, 2026
What it owns · $509m
Short-term assets $253mLonger-term assets $256m
What it owes, and who funded it · $509m
Short-term liabilities $56mLonger-term liabilities $114mShareholders' equity $339m
  • Short-term assets cover short-term liabilities $253m of assets due within a year against $56m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $253m short-term assets against $114m of longer-dated liabilities.
  • More cash than debt $17m of cash against $101m of debt.
  • Debt below 40% of shareholders' equity Debt is 30% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 30% over five years.
  • A year's operating cash flow covers at least 20% of debt $12m of operating cash flow against $101m of debt.
  • Operating profit covers interest at least five times over Operating income of −$25m against $9m of interest.

From Orthopediatrics Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

35 /100

Weak moat

How hard Orthopediatrics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -8.6% of total assets over 9 years.

  • Pricing power 20 / 20

    Gross margin has been a median 74.4%, moving by 1.3 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -18.3%; its worst year was -27.4%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -25.3% of revenue.

  • Discipline 4 / 20

    The diluted share count rose 24.1% over five years; stock-based pay has been a median 6.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: KIDS vs LMATAXGN vs KIDSCERS vs KIDSESTA vs KIDS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Orthopediatrics Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Orthopediatrics Corp.